KL-6 is known as a useful serum biomarker of the disease activity in interstitial pneumonias. We investigated its usefulness as a biomarker for subtyping intraductal papillary mucinous neoplasms (IPMNs) of the pancreas. IPMNs are generally divided into 4 subtypes, namely pancreatobiliary (PB), intestinal (INT), gastric (GS), and oncocytic (ONC). Aside from the KL-6 antibody, the MUC1, MUC2, MUC5AC, MUC6, and MIB-1 antibodies were also examined. Eighteen IPMN cases were examined, including 12 cases of intraductal papillary mucinous carcinomas (IPMCs) simultaneously associated with dysplasia (IPMDs) and hyperplasia (IPMHs) and 6 IPMD cases with IPMH. KL-6 antibody was positive in the 8 IPMC cases, corresponding to a MUC2-negative PB subtype, but negative in 4 IPMC cases, corresponding to the INT subtype, which is positive for MUC2. IPMD of moderate-to-severe degree positively stained for the KL-6 antibody in the IPMC cases of the PB subtype but not in those of the INT subtype. The IPMH cases were mostly negative for KL-6, similar to the mild IPMD cases. In the 6 cases of mild IPMD and/or IPMH, KL-6 and MUC2 expressions were mostly negative. In conclusion, the KL-6 antibody is immunohistochemically a good biomarker of the PB subtype of IPMC, but not the INT subtype. Identifying IPMN subtypes based on KL-6 stainability would be useful. Clinicopathological studies with more IPMC cases might be needed for further progress in this field of study.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00795-014-0080-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical characteristics and prognostic factors for MPO-ANCA positive interstitial lung disease: A comparative study of ANCA associated vasculitis (AAV)-ILD and pulmonary limited vasculitis.
Respir Investig
November 2024
Department of Respiratory Medicine, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan.
Article Synopsis
- This study investigates the impact of microscopic polyangiitis (MPA) on patients with interstitial lung disease (ILD), focusing on their clinical characteristics and treatment outcomes.
- Within a sample of 114 patients, those diagnosed with ANCA-associated vasculitis with ILD (AAV-ILD) were found to have better survival rates and treatment responses compared to those with pulmonary limited vasculitis (PLV).
- The findings emphasize the critical role of accurate diagnosis and treatment planning, suggesting that HRCT imaging and corticosteroid response are vital for understanding patient prognosis.
Mycophenolate mofetil after tacrolimus for refractory clinically amyopathic dermatomyositis: a case report.
Front Pharmacol
October 2024
The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, Guangdong, China.
Article Synopsis
- Dermatomyositis (DM) with anti-MDA5 antibodies, particularly when associated with rapidly progressive interstitial lung disease (RP-ILD), is considered hard to treat.
- A significant case of clinically amyopathic dermatomyositis (CADM) with RP-ILD demonstrated a poor response to conventional treatments but improved after adding mycophenolate mofetil (MMF), leading to controlled symptoms and decreased antibody levels.
- The report emphasizes the need for more research to better understand the role of inflammatory cytokines in CADM/RP-ILD and to explore MMF's potential for long-term treatment.
Biomarkers of rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis.
Front Immunol
November 2024
Department of Respiratory Diseases, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, Henan, China.
Background: Interstitial Lung Disease (ILD) represents the most common extra-articular manifestation of Rheumatoid Arthritis (RA) and is a major cause of mortality. This study aims to identify and evaluate biomarkers associated with Rheumatoid Arthritis-Associated Interstitial Lung Disease (RA-ILD).
Methods: We searched PubMed, Cochrane Library, EMBASE, and Web of Science databases for studies related to biomarkers of RA-ILD up until October 7, 2023.
Short-term efficiency of plasma exchange in combination with immunosuppressants and/or biologics in the treatment of idiopathic inflammatory myopathy with rapidly progressive interstitial lung disease: a systematic review and meta-analysis.
Ann Med
December 2024
Department of Rheumatology and Immunology, People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, China.
Article Synopsis
- Rapidly progressive interstitial lung disease (RP-ILD) is a serious complication in patients with idiopathic inflammatory myopathy (IIM), often leading to poor outcomes, making the need for effective treatments essential.
- Plasma exchange (PE) may help by quickly removing harmful substances from the blood, and this study assesses its effectiveness when combined with immunosuppressants in improving survival rates and reducing inflammatory markers.
- Results showed an 80% survival rate at 6 months for patients undergoing PE, which was significantly better than for those not receiving PE, suggesting its potential as a beneficial treatment option for IIM-RP-ILD.
Risk prediction modelling in idiopathic inflammatory myositis-associated interstitial lung disease based on seven factors including serum KL-6 and lung ultrasound B-lines.
Clin Exp Rheumatol
October 2024
Department of Rheumatology and Immunology, Shantou Central Hospital, Shantou, China.
Article Synopsis
- The study aimed to create an easy-to-use nomogram for predicting interstitial lung disease (ILD) in patients with idiopathic inflammatory myositis (IIM) based on a large retrospective analysis of 205 patients from Shantou Central Hospital.
- Using LASSO regression, researchers identified four risk factors (age, respiratory symptoms, MDA-5 antibodies, and anti-ARS antibodies) and found that including KL-6 levels and LUS B-lines significantly improved the model's predictive accuracy.
- The final model showed strong predictive performance with an ROC AUC of up to 0.951, and a web version was created to enhance accessibility for clinicians.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!